QIOU GU¹, CHUILIN LAI¹, XIAO GUAN¹, JING ZHU², TIAN ZHAN¹, JIANPING ZHANG^1,*

BIOCELL, Vol.48, No.2, pp. 253-269, 2024, DOI:10.32604/biocell.2023.028336

Abstract Objectives: Colorectal cancer (CRC) is a serious threat to human health worldwide. Oxaliplatin is a platinum analog and is widely used to treat CRC. However, resistance to oxaliplatin restricts its effectiveness and application while its target recognition and mechanism of action also remain unclear. Therefore, we aimed to develop an oxaliplatin-resistant prognostic model to clarify these aspects. Methods: We first obtained oxaliplatin-resistant and parental cell lines, and identified oxaliplatin-resistant genes using RNA sequencing (RNA-seq) and differential gene analysis. We then acquired relevant data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Cox regression and Least Absolute… More > Graphic Abstract

LIANLI NI^1,2,#, YUN YU^1,2,#, HAN LIN^1,2, WEISHAN ZHUGE², LU TAO², YIWEI SHEN², RI CUI^2,*, SHAOTANG LI^1,2,*

BIOCELL, Vol.47, No.10, pp. 2245-2254, 2023, DOI:10.32604/biocell.2023.030147

Abstract Background: Homeobox B8 (HOXB8), a member of HOX family, plays a key role in the development of colorectal cancer (CRC). However, the function of HOXB8 in oxaliplatin (OXA) resistance in CRC is still unclear. This study investigated the role and precise molecular mechanism of HOXB8 in OXA-resistant CRC cells. Methods: The cell viability was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, and the colony forming ability was determined by colony formation assay. The silencing RNA (siRNA) approach was used to knockdown HOXB8 in CRC cells while the lentiviral transfection system was used to establish stable HOXB8 overexpressing CRC… More >

Wei Wei^*1, Xiao-Dong Ma^†1, Guan-Min Jiang^‡, Bin Shi^§, Wen Zhong^¶, Chun-Lei Sun^§, Liang Zhao^*, Yan-Jiao Hou^*, Hao Wang^*

Oncology Research, Vol.28, No.4, pp. 423-438, 2020, DOI:10.3727/096504020X15877284857868

Abstract Although oxaliplatin serves as one of the first-line drugs prescribed for treating colorectal cancer (CRC), the therapeutic effect is disappointing due to drug resistance. So far, the molecular mechanisms mediating oxaliplatin resistance remain unclear. In this study, we found the chemoresistance in oxaliplatin-resistant HCT116 cells (HCT116/OXA) was mediated by the upregulation of ERCC1 expression. In addition, the acquisition of resistance induced epithelial–mesenchymal transition (EMT) as well as the Slug overexpression. On the contrary, Slug silencing reversed the EMT phenotype, decreased ERCC1 expression, and ameliorated drug resistance. Further mechanistical studies revealed the enhanced Slug expression resulted from the activation of AKT/… More >

Ching-Wen Huang^*, Cheng-Jen Ma^*†, Wei-Chih Su^*, Yi-Ting Chen^‡§, Hsiang-Lin Tsai^*¶, Yung-Sung Yeh^*#, Tsung-Kun Chang^*, Wen-Hung Hsu^**††, Fang-Jung Yu^**††, Jaw-Yuan Wang^{*¶‡‡§§¶¶##}

Oncology Research, Vol.28, No.7-8, pp. 701-714, 2020, DOI:10.3727/096504020X15986099915822

Abstract This study evaluated the survival effects of metronomic maintenance therapy with oral fluoropyrimidine in patients with stage III colorectal cancer (CRC) according to epidermal growth factor receptor (EGFR) expression. We enrolled 197 patients with stage III CRC who had undergone radical resection and FOLFOX regimen adjuvant chemotherapy. The clinicopathological features and effects of metronomic maintenance therapy with oral capecitabine (daily dose of 850 mg/m2 , twice daily, on days 1–14 every 3 weeks for 6 months) on survival according to treatment group and EGFR expression were analyzed. By conducting an in vitro cell line study and in vivo study through… More >